Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer sides with Merck KGaA on PD-L1; AZ deal out for good?

This article was originally published in Scrip

Executive Summary

Pfizer and Merck KGaA's plans to jointly develop the latter's anti-PD-L1 drug is positive news for all in the field.

You may also be interested in...



Pfizer’s Avelumab Poised For Speedy Review By FDA

Avelumab could be the fourth PD-1/L1 inhibitor to reach the market now that the US FDA has accepted Pfizer’s and Merck KGaA’s BLA for priority review in the treatment of metastatic Merkel cell carcinoma.

Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts

Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.

Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts

Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC026941

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel